	US 11,944,593 B2
	Myrcene-containing complex mixtures targeting TRPV1
Andrea Small-Howard, Norwalk, CA (US); and Helen Turner, Honolulu, HI (US)
Assigned to GBS GLOBAL BIOPHARMA, INC., Ottawa (CA)
Filed by GBS GLOBAL BIOPHARMA, INC., Ottawa (CA)
Filed on May 19, 2020, as Appl. No. 16/878,295.
Application 16/878,295 is a division of application No. 15/986,316, filed on May 22, 2018, granted, now 10,709,670.
Claims priority of provisional application 62/509,546, filed on May 22, 2017.
Prior Publication US 2020/0390721 A1, Dec. 17, 2020
Int. Cl. A61K 31/01 (2006.01); A61K 9/00 (2006.01); A61K 31/015 (2006.01); A61K 31/045 (2006.01); A61K 31/05 (2006.01); A61K 31/192 (2006.01); A61K 31/352 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61P 29/02 (2006.01)

CPC A61K 31/01 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/006 (2013.01); A61K 9/0073 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/192 (2013.01); A61K 31/352 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61P 29/02 (2018.01); A61K 2236/51 (2013.01)]

20 Claims

1. A method of treating a disease in a mammalian subject, comprising:

administering to the subject an effective amount of the pharmaceutical composition comprising:

myrcene;

at least one cannabinoid and/or terpene other than myrcene; and

a pharmaceutically acceptable carrier or diluent,

wherein the composition comprises no more than 20 different species from a total set of cannabinoid and terpene compounds, and is substantially free of THC, and

wherein the disease is selected from the group consisting of cardiac hypertrophy, overactive bladder and refractory chronic cough.